Singapore markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
47.75+1.01 (+2.16%)
At close: 4:00PM EDT
Sign in to post a message.
  • P
    Pandora
    I just put in an order to buy more Agios shares at $45.18, its closing price on Friday, September 10th; I'm hoping I'll get it for that price this morning, Monday, September 13th. Analysts have Agios' one-year price target at a high of $93, median of $61, and low of $39. The company, its research, and management are pure gold. It reminds me of Regeneron, which was constantly under attack on message boards by shorts as a loser company -- and what happened to Regeneron? It remained at $20 for around 20 years -- something like that -- but now it's at $650 per share. A similar golden fate is awaiting Agios. I doubt we'll have to wait more than a couple of years for Agios to shine big, and this year, 2021/2022, should see a considerable increase in share price once their mitapivat is approved by the FDA and EMA. Brilliant company founded by cream-of-the-crop hematologists/oncologists.
  • P
    Pandora
    CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:
    Citi’s 16th Annual Biopharma Virtual Conference
    Panel: Sickle Cell, Beta-Thal, ITP & PKD - Measuring Industry Progress in Benign Hematology
    Friday, September 10 at 12:30 p.m. ET
    2021 Cantor Virtual Global Healthcare Conference
    Monday, September 27 at 8:00 a.m. ET
    Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

    About Agios
    Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. The company’s most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to its active late-stage clinical pipeline, Agios has multiple novel, investigational therapies in clinical and preclinical development.
  • P
    Pandora
    Those who are shorting Agios will soon be going nuts and swarming the message boards with negative, even vicious, lies about Agios. Why now? Because even the shorts themselves can see and smell that their jig is up, that Agios will soon -- within the next several months, at the latest -- be granted approval both in The States and in Europe for Mitapivat, and then its off to the races. In 2022, Agios will complete two trials on sickle cell/thalassemia, and more.
  • G
    Govbailout
    Company still buying back stock at a heavy rate. Can't believe this is still under $100
  • P
    Pandora
    On Wednesday, September 1, 2021, JP Morgan raised Agios' price target from $57 to $61; Agios will have a presentation on sickle cell at Citi's Biopharma Conference on September 10th and have another presentation at Cantor Fitzgerald's Global Healthcare Conference on September 27th. Agios was founded by the greatest oncological and hematological minds in the USA.
  • J
    Julio
    Pandora …a second week of Sept has slipped away….and so has any UP in AGIO…tik tok tik tok to your illustrious analysis and profound insight to intrinsic value being displayed in the second half of 2021, after 96 days towards a higher value from June 7th, yet , hmmmmmmm, only to show negative results !!!
    Where you talking the Bucs versus the Cowboys ??? Well, yes Brady has that ability as you saw, but FOUSE and SCHENKEIN, together aren’t TOM BRADY.
  • P
    Pandora
    Hooray on August 17, 2021: Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency. They also submitted the same indication to the European Medicine Agency (EMA) and are waiting to hear on it. Go Agios.
  • P
    Pandora
    The hedgie shorts, in particular, and some options players are getting desperate, grasping at straws, bringing out their media arms against Agios Pharmaceuticals because they're seeing the tide change and know that Agios will be moving up, with drug approvals by the FDA and EMA within the next several months. Agios onwards and upwards.
  • J
    Julio
    Pandora ..Shhhhh…you can already hear the ….slideee for tomorrow
  • J
    Julio
    Pandora …afternoon…you know the news comes on at 6PM each night like clock work. It never costs you a thing….WELL, AGIO, goes DOWN every afternoon against all analysts at 3:30 PM !!! But it costs you. But it does conform to the hour, just like the news !!! ..🤣🤣🤣🤣…tic tok , tic tok
  • J
    Julio
    Entering the afternoon slide, shareholder will see their investment erode away, like always each afternoon. Almost like, knowing that the News will be on at 5PM. ( only no one loses on the News , !!! Lol )
  • J
    Julio
    Fouse..resign, hand over the company to the hands of a seasoned CEO with credibility. I saw the constant selling of shares each time the value rose , lol, above 44…Time to admit, you are not a credible CEO…43.97, what a laugh, and a sin for shareholders.
  • P
    Pandora
    Goldman Sachs is the only -- repeat, only -- analyst who lowered their rating of Agios Pharmaceuticals recently: HC Wainwright, Canaccord, Oppenheimer all have buy or hold ratings, and Wainwright upped its price target to $93. Goldman Sachs is undoubtedly shorting Agios or in some way has a vested interest in seeing Agios' price drop. Agios recently submitted an NDA to the FDA and an MMA to the EMA, and both hopefully should be approved. We're on our way up.
  • J
    Julio
    Pandora !!! Another day of declines?they keep adding up, NONE in your favor as to higher value, 2nd half of 2021. I read the BS, Fouse said she would rather do a buy back and create value for shareholders, rather than a dividend. I knew that was BS, and was a lame excuse. I?d say she has destroyed on multiple fronts, shareholder confidence, ( longs are selling, Bellevue Group) and the company?s market cap, and ability to create value. This #$%$ has fallen every day except one, since June 6, and they claim to be a leader in their space. BS. September is around the corner Pandora, you want more days in that month !!!! Lol. Back now to Fouse?s hiring price 43, dec 2020?.she has done a world of good for 16M in salary ?, no value created for shareholders, under her reign, and science mgmt left, as well.
  • J
    Julio
    Pandora , 🤔🤔🤔🤔, don’t good biotechs go, hmmm, up, on good news from the FDA ??? …strange that value here at Agio, continues to erode !!! Even with semi good news..😂😂😂😂
  • P
    Pandora
    @Julio -- You're obsessed with Agios Pharmaceuticals and its CEO Jackie Fouse to the point where you're not thinking clearly. You're on this board multiple times a day, every day, for what seems like years -- which is already very telling. Please get some perspective. I don't know if you're shorting Agios, if you're a paid shill employed by corporate shorts, if you're invested in a competing biotech, if you're a disgruntled former employee/foe/friend, or simply if you're an aggrieved investor, but Agios is a great company. It's run by the most brilliant hematologists/oncologists in the world, period. I have no doubt that it'll be quite successful and lavished with praise for its work in genetic disease and cancer. What you write is all very distortive and nonsensical. I will not be responding to you again. Good luck in life.
  • P
    Pandora
    July 2021, H.C. Wainwright analyst Michael King has just given Agios Pharmaceuticals a Buy rating, setting a price target of $93. According to TipRanks, Michael King is currently ranked with 5 stars on a 0-to-5 stars scale, and his average return is 28.4% and his success rate is 56.93%.
  • J
    Julio
    Slide
  • J
    Julio
    Pandora ..don’t think you’ll hace competition for your lot of a hundred shares at even 44…so wait !!!..or wait forever your HIGHER PRICES a of 2nd half of 2021 …🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣
  • J
    Julio
    Well Pandora your clock is ticking, 11 days ago you said 2nd half of the year a higher stock price. 11 passed, you are still seeing a declining stock price , yet I’ve watched it decline for 60 days and counting !!! June was a promo for Bowden to get out before the submission of the NDA and the quiet period. HE WANTED OUT. OUT OF THE FOUSE HOUSE.